[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350595-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350595-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","oncogenic-egfr-signaling-as-a-central-regulator-of-chemoresistance-in-ovarian-cancer-a-mechanistic-review","Oncogenic EGFR Signaling as a Central Regulator of Chemoresistance in Ovarian Cancer - A Mechanistic Review","","Ovarian cancer (OVC) is a leading cause of gynecological cancer mortality due to late-stage diagnosis and chemoresistance. Oncogenic EGFR signaling coordinates tumor progression and drug resistance by activating PI3K/AKT/mTOR, MAPK/ERK, and JAK/STAT pathways. Together they promote proliferation, inhibit apoptosis, maintain cancer stem cells, and drive EMT, reducing sensitivity to platinum and taxane therapies. The review also integrates EGFR cross-talk with ECM, metabolic reprogramming, immune evasion, hypoxia, and extracellular vesicle signaling, and discusses limitations of current EGFR-targeted therapy to support future combinatorial strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/oncogenic-egfr-signaling-as-a-central-regulator-of-chemoresistance-in-ovarian-cancer-a-mechanistic-review/350595/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/oncogenic-egfr-signaling-as-a-central-regulator-of-chemoresistance-in-ovarian-cancer-a-mechanistic-review/350595.png","ImageObject",300,407,{"name":42,"@type":43},"Fans","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why does ovarian cancer develop chemoresistance?","Question",{"text":63,"@type":64},"Chemoresistance arises from interconnected signaling networks in which oncogenic EGFR drives tumor progression and drug resistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which EGFR-related pathways are highlighted as key regulators?",{"text":68,"@type":64},"The review focuses on PI3K/AKT/mTOR, MAPK/ERK, and JAK/STAT signaling cascades and their coordinated effects on resistance.",{"name":70,"@type":61,"acceptedAnswer":71},"How do these pathways contribute to reduced chemotherapy sensitivity?",{"text":72,"@type":64},"They confer resistance through proliferation and antiapoptotic effects, cancer stem cell maintenance, and EMT, which together decrease sensitivity to platinum-based and taxane therapies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350595,1790199643,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Review  \nOncogenic EGFR Signaling as a Central Regulator of  \nChemoresistance in Ovarian Cancer: A Mechanistic Review  \nArulkumar Nagappan 1, *, Veeran Sethuraman 2, Parthiban Pandian 1, Jothi Nedunchezhian 3 and Arvind Kumar Shukla 4, *  \nAcademic Editor: Daniela Miricescu  \nReceived: 29 May 2026  \nRevised: 30 June 2026  \nAccepted: 30 June 2026  \nPublished: 1 July 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Pathology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Thandalam, Chennai 602105, Tamil Nadu, India; [dr.parthi2009@gmail.com](dr.parthi2009@gmail.com)  \n2 Department of Orthopaedics, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai 602105, Tamil Nadu, India; [sethuramanbio@gmail.com](sethuramanbio@gmail.com)  \n[3](3 PG & Research Department of Biotechnology & Bioinformatics)[ PG & Research Department of Biotechnology & Bioinformatics](3 PG & Research Department of Biotechnology & Bioinformatics), [Holy Cross College](Holy Cross College) ([Autonomous](Autonomous)), Affiliated to Bharathidasan University, Tiruchirappalli 620002, Tamil Nadu, India; [jothi@hcctrichy.ac.in](jothi@hcctrichy.ac.in)  \n4 School of Biomedical Convergence Engineering, Pusan National University, Yangsan 50612, Republic of Korea  \n* Correspondence: [arulbiotechtnau@gmail.com](arulbiotechtnau@gmail.com) (A.N.); [arvindkumarshuklapnu@gmail.com](arvindkumarshuklapnu@gmail.com) (A.K.S.)  \nAbstract  \nOvarian cancer (OVC) is a leading cause of gynecological cancer mortality due to late-stage diagnosis and chemoresistance. Among the multiple molecular mediators, oncogenic epidermal growth factor receptor (EGFR) signaling has emerged as a key regulator of tumor progression and drug resistance, ultimately governing cancer survival. Therefore, this review focused on the molecular mechanisms of aberrant EGFR signaling to promote chemoresistance in ovarian cancer through multiple interlinking pathways, including thephosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of the rapamycin (mTOR), mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling cascades. These pathways act in concert to confer resistance, including proliferation, antiapoptotic effects, cancer stem cell maintenance, and facilitating epithelialmesenchymal transition (EMT), which function together to decrease sensitivity towards platinum-based and taxane chemotherapies. Furthermore, we incorporate novel evidence regarding EGFR cross-talk with extracellular matrix (ECM) and metabolic reprogramming, especially their relevance to immune evasion mechanisms, hypoxia, and extracellular vesicles (EVs)-mediated signaling. In addition, we elaborated on the limitation of the current EGFR targeting therapy, which will be beneficial for further designing new combinatorial treatment approaches by using EGFR inhibitors with immunotherapy, nanocarriers, and microbiota modulators. Overall, this review highlights the updated role of EGFR signaling as a key regulator of chemoresistance in ovarian cancer, providing insights for developing targeted therapies to overcome drug resistance and improve patient survival.  \nKeywords: ovarian cancer; EGFR; chemoresistance; targeted therapy; tumor microenvironment; EMT; cancer stem cells  \n1. Introduction  \nOvarian cancer (OVC) is one of the most lethal forms of gynecological cancer, as it causes a great public health concern in terms of its advanced stage of detection, tendency to recur, and minimal success in achieving positive therapeutic results [1,2] . Epidemiologically, epithelial ovarian cancer (EOC) accounts for a","cbCaifGfBOSZGWXz","https://ap.wps.com/l/cbCaifGfBOSZGWXz","pdf",1568136,29,"English","# Introduction\n# Abstract\n# Keywords","[{\"question\":\"Why does ovarian cancer develop chemoresistance?\",\"answer\":\"Chemoresistance arises from interconnected signaling networks in which oncogenic EGFR drives tumor progression and drug resistance.\"},{\"question\":\"Which EGFR-related pathways are highlighted as key regulators?\",\"answer\":\"The review focuses on PI3K/AKT/mTOR, MAPK/ERK, and JAK/STAT signaling cascades and their coordinated effects on resistance.\"},{\"question\":\"How do these pathways contribute to reduced chemotherapy sensitivity?\",\"answer\":\"They confer resistance through proliferation and antiapoptotic effects, cancer stem cell maintenance, and EMT, which together decrease sensitivity to platinum-based and taxane therapies.\"}]","Oncogenic EGFR Signaling as a Central Regulator of Chemoresistance in Ovarian Cancer - A Mechanistic Review | PDF",1790089798,73,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/791c80b27dac5cccb1e4fb57de2cacd9.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aeded25c466536f127468c4db4a24d62.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4554655e6cffc94200b3cdb6d23e95ff.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d263eeb3dbe093b578b3155be7e809c.webp",980,1385]